Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 16

1.

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.

Patrick AR, Avorn J, Choudhry NK.

Circ Cardiovasc Qual Outcomes. 2009 Sep;2(5):429-36. doi: 10.1161/CIRCOUTCOMES.108.808592. Epub 2009 Jul 21.

2.

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.

Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL.

Pharmacoeconomics. 2010;28(1):61-74. doi: 10.2165/11318240-000000000-00000.

PMID:
20014877
3.

Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin.

Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA.

J Gen Intern Med. 2009 May;24(5):656-64. doi: 10.1007/s11606-009-0949-1. Epub 2009 Mar 21. Review. Erratum in: J Gen Intern Med. 2009 Dec;24(12):1358.

4.

Estimation of the warfarin dose with clinical and pharmacogenetic data.

International Warfarin Pharmacogenetics Consortium., Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA.

N Engl J Med. 2009 Feb 19;360(8):753-64. doi: 10.1056/NEJMoa0809329. Erratum in: N Engl J Med. 2009 Oct 15;361(16):1613. Dosage error in article text.

5.

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.

Eckman MH, Rosand J, Greenberg SM, Gage BF.

Ann Intern Med. 2009 Jan 20;150(2):73-83.

PMID:
19153410
6.

Warfarin pharmacogenetics.

Limdi NA, Veenstra DL.

Pharmacotherapy. 2008 Sep;28(9):1084-97. doi: 10.1592/phco.28.9.1084. Review.

7.

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL.

Thromb Haemost. 2008 Aug;100(2):229-39.

PMID:
18690342
8.

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians..

Chest. 2008 Jun;133(6 Suppl):160S-198S. doi: 10.1378/chest.08-0670.

PMID:
18574265
9.

Genetic determinants of response to warfarin during initial anticoagulation.

Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM.

N Engl J Med. 2008 Mar 6;358(10):999-1008. doi: 10.1056/NEJMoa0708078.

10.

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.

Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O'Kane D, Schulman K, Veenstra D, Williams MS, Watson MS; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use..

Genet Med. 2008 Feb;10(2):139-50. doi: 10.1097/GIM.0b013e318163c35f.

PMID:
18281922
11.

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.

Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF; Couma-Gen Investigators..

Circulation. 2007 Nov 27;116(22):2563-70. Epub 2007 Nov 7.

12.

Warfarin pharmacogenetics: economic considerations.

Hughes DA, Pirmohamed M.

Pharmacoeconomics. 2007;25(11):899-902. No abstract available.

PMID:
17960949
13.

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

Caraco Y, Blotnick S, Muszkat M.

Clin Pharmacol Ther. 2008 Mar;83(3):460-70. Epub 2007 Sep 12.

PMID:
17851566
14.

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.

Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT.

Clin Pharmacol Ther. 2008 Feb;83(2):312-21. Epub 2007 Jul 25.

15.

The cost-effectiveness of warfarin pharmacogenomics.

Veenstra DL.

J Thromb Haemost. 2007 Sep;5(9):1974-5. Epub 2007 Jul 23. No abstract available.

16.

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE.

JAMA. 2002 Apr 3;287(13):1690-8.

PMID:
11926893

Supplemental Content

Support Center